$CBIO News

HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target

Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027

HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors

Crescent Biopharma Announces Grants of Inducement Awards

The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady

Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Crescent Biopharma to Present at September Investor Conferences

Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms Undisclosed

Crescent Biopharma Files Prospectus For Offering $500M Mixed Shelf

Crescent Biopharma: Intriguing Developer Of ADC / PD1-VEGF Assets May Not Be Sufficiently Derisked